Allogene's Dual-Targeted CAR-T Shows Promise in Autoimmune Pre-Clinical Data
Event summary
- Allogene Therapeutics published pre-clinical data for ALLO-329, a dual-targeted CD19/CD70 CAR T therapy, in Nature Communications.
- The data demonstrate ALLO-329's ability to eliminate B and T cells in systemic lupus erythematosus (SLE) models, halting autoantibody production.
- A Phase 1 RESOLUTION trial is enrolling patients and expects initial data in June 2026, with a broader update planned for year-end.
- ALLO-329 received three FDA Fast Track Designations for lupus, myositis, and scleroderma in April 2025.
- The therapy utilizes Allogene's Dagger® technology to potentially reduce or eliminate the need for lymphodepletion.
The big picture
Allogene's ALLO-329 represents a significant effort to expand the application of CAR-T therapy beyond oncology into the large and underserved autoimmune disease market. The dual-targeting approach, combined with the Dagger® technology, aims to overcome key barriers to CAR-T adoption in autoimmune indications, such as the need for intensive lymphodepletion. Success here could unlock a multi-billion dollar market opportunity, but the clinical data will be crucial to validating the approach.
What we're watching
- Clinical Efficacy
- The June 2026 data release from the RESOLUTION trial will be critical in assessing whether ALLO-329's pre-clinical promise translates to meaningful clinical responses in patients with autoimmune diseases.
- Lymphodepletion
- The trial’s parallel cohorts, one with reduced lymphodepletion and one with none, will reveal whether ALLO-329 can achieve efficacy without the intensive pre-treatment, a key differentiator for broader adoption.
- Competitive Landscape
- The success of ALLO-329 will be weighed against competing CAR-T programs, many of which are pursuing higher cell doses, and will determine if Allogene's lower dose approach can establish a sustainable competitive advantage.
Related topics